Track Amneal Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Amneal Pharmaceuticals, Inc. AMRX · Stock Open Amneal Pharmaceuticals, Inc. in new tab

21.38 USD
P/E
53.45
EPS
0.40
P/B
14.02
ROE
70.00
Beta
1.21
Target Price
24.29 USD
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc.

🧾 Earnings Recap – Q3 2025

Amneal Pharmaceuticals delivered a robust Q3 2025 performance, achieving revenues of $785 million and adjusted EBITDA of $160 million, marking consistent growth driven by a diversified portfolio.

  • Specialty segment growth led by CREXONT for Parkinson's disease, with projected peak U.S. sales of $300 million to $500 million.
  • Successful launch of the BREKIYA autoinjector, the first self-administration product for migraine, addressing a significant patient need.
  • Strong momentum in GLP-1 collaboration with Metsera, with plans to establish two state-of-the-art production facilities.
  • Anticipating 20 to 30 new product launches annually, with 17 already launched in 2025 and 13 more awaiting approval.
  • Continued focus on complex generics and biosimilars, with 69 ANDAs pending, 64% categorized as complex products.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 26, 2027
P/E53.45
EPS0.40
Book Value1.53
Price to Book14.02
Debt/Equity512.38
% Insiders52.323%
Growth
Revenue Growth0.10%
Earnings Growth1.57%
Estimates
Forward P/E17.34
Forward EPS1.23
Target Mean Price24.29

DCF valuation

Model fair value for Amneal Pharmaceuticals, Inc. (AMRX)
Result
Sign in to run the valuation for AMRX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus Strong buy · mean target 24.29 USD (low 20.00, high 28.00) · as of 14 Nov 2026
Low 20.00
Mean 24.29
High 28.00
Price 21.38
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Amneal Pharmaceuticals, Inc. Logo Amneal Pharmaceuticals, Inc. Analysis (AMRX)

United States Health Care Official Website Stock

Is Amneal Pharmaceuticals, Inc. a good investment? Amneal Pharmaceuticals, Inc. (AMRX) is currently trading at 21.38 USD. Market analysts have a consensus price target of 24.29 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 53.45. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Amneal Pharmaceuticals, Inc. is expected to release its next earnings report on Feb. 26, 2027. The market consensus estimate for Forward EPS is 1.23.

Investor FAQ

Does Amneal Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Amneal Pharmaceuticals, Inc.?

Amneal Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 26, 2027. The company currently has a trailing EPS of 0.40.

Company Profile

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Exchange Ticker
NYQ (United States) AMRX
FRA (Germany) 2DT.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion